Confidential Data Plan

Learn what the EU AI Act Digital Omnibus changes mean for pharma, including delayed high-risk AI deadlines, GDPR updates, and practical compliance steps for 2027.

Learn why public AI tools pose data privacy risks for pharma organizations, how AI differs from search engines, and how to use AI safely without exposing confidential research.

General AI writing tools are not built for private data. Learn the risks and why secure alternatives matter for sensitive content.

A secure, private alternative to Claude for handling confidential content with strong data protection and full control.

A secure, private alternative to Gemini for handling confidential content with strong data protection and full control.

Discover secure alternatives to Grammarly for confidential content, prioritizing privacy and data protection in sensitive writing tasks.

Explore secure alternatives to ChatGPT for sensitive writing, focusing on privacy, data protection, and confidentiality in business communications.

Executives are reconsidering AI for strategic writing due to concerns about authenticity, control, and long-term business impact.

Discover how businesses can lose competitive advantage during the draft stage and the key factors that contribute to this risk.

Explore how AI writing tools can lead to premature strategic disclosure and its potential risks in business decision-making.

A guide to why board level drafts require higher security and governance than typical content in AI tools.

Learn why even short-term data storage can be risky with AI writing tools for regulated or high security teams.